Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 6, 2017

PC4C to intiate diagnostic study of brain tumours with NantHealth’s GPS cancer test

The Philadelphia Coalition for a Cure (PC4C) is planning to begin a diagnostic study of adult and pediatric brain tumours with NantHealth's GPS cancer test, in collaboration with Children's Hospital of Orange County (CHOC).

The Philadelphia Coalition for a Cure (PC4C) is planning to begin a diagnostic study of adult and pediatric brain tumours with NantHealth's GPS cancer test, in collaboration with Children's Hospital of Orange County (CHOC).

NantHealth, a personalised healthcare firm, will provide participating study researchers with its  molecular profiling and diagnostic GPS cancer test, to identify treatment strategies for the patients.

The test is a molecular scan which integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry.

"Our goal in elevating the potential of combination immunotherapy as the new paradigm of cancer care is so that oncologists can offer their patients a less rigid therapy and one that is targeted at the patient's unique biology."

It enables determination of personalised treatment strategies by providing the molecular profile of a patient's cancer and an assessment of protein pathway function.

NantHealth founder and chief executive officer Patrick Soon-Shiong said: "The current standard of treatment for patients who have been diagnosed with brain tumours remains along the callous path of chemotherapy and/or radiation.

"Our goal in elevating the potential of combination immunotherapy as the new paradigm of cancer care is so that oncologists can offer their patients a less rigid therapy and one that is targeted at the patient's unique biology to harness the power of the immune system to fight cancer the way it was designed to do."

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

GPS cancer scanning is performed in CLIA-certified and CAP-accredited laboratories. It is currently available through Independence Blue Cross (Independence) for eligible members.

The PC4C intends to offer the test coverage for non-Independence insured brain tumour patients through grant support of the research study.

A clinical diagnostics and research initiative, PC4C aims to assess, promote and facilitate the use of technologies and clinical diagnostics on behalf of patients diagnosed with brain and other cancers.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU